Albemarle, a global developer, manufacturer and marketer of highly engineered specialty chemicals, has begun upgraded and expanded its FDA-registered multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility in South Haven, Mich.
This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios. In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status.
Production using the new expanded capacity commenced on June 1, 2012.